Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Myelodysplastic Syndromes Myelodysplastic Syndromes

637. Myelodysplastic Syndromes—Clinical Studies: Treatment of Higher Risk Myelodysplastic syndromes

Watch Session

653 Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS) from Study P-2001 (NCT02610777)

Mikkael A. Sekeres, Justin M. Watts, Atanas Radinoff, et al.

 

654 Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial

Raphael Itzykson, Valeria Santini, Cendrine Chaffaut, et al.

 

655 Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS) clinically relevant abstract

Nathan Radakovich, David A. Sallman, Rena J. Buckstein, et al.

 

656 Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study clinically relevant abstract

Jacqueline S. Garcia, Andrew H. Wei, Uma Borate, et al.

 

657 Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, et al.

 

658 Treatment with Imetelstat Provides Durable Transfusion Independence (TI) in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) clinically relevant abstract

Uwe Platzbecker, Pierre Fenaux, David P. Steensma, et al.